Fourteen evaluable advanced breast cancer patients, extensively pretreated by chemotherapy, received a combination of cisplatin (DDP) and etoposide (VP 16). DDP was given at 60 or 100 mg/m2 on day 1, and VP 16 at 120 mg/m2 on days 1, 2 and 3; cycles were repeated every 4 weeks. Major responses were never obtained; a minor response in 1 patient, no change in 7 patients, and progression in 6 patients were observed. Main side effects were nausea and vomiting (62% severe), and leukopenia (31% leukocytes < 2,000/mm3). Two patients refused further treatment due to intense nausea and vomiting. DDP-VP 16 combination chemotherapy is ineffective and poorly tolerated in heavily pretreated breast cancer patients.
AthanassiadesP., BacoyiannesH., KontoyiannesD.: Etoposide (VP16.213) and cis-dichlorodiammi-neplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.Chemioterapia, 2: 125–127, 1986.
3.
BullJ.M., AndersonT., LippmanM.E., CassidyJ.G., GormleyP.E., YoungR.C.: A phase II trial of cis-dichlorodiammineplatinum II in breast and ovarian carcinomas.Proc. AACR and ASCO, 19: 87, 1978.
4.
BurchenalJ.H., KalaherK., LokysL.: Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives.Biochimie, 60: 961–965, 1978.
5.
CocconiG., TonatoM., Di CostanzoF., BisagniG., BelsantiV., BuzziF., CeciG.: Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).Eur. J. Cancer Clin. Oncol., 22: 761–764, 1986.
6.
DhafirR.A., EinhornL., WilliamsS., RosenbaumP., IsselB.: The effect of etoposide (VP-16), used alone or in combination on the survival of patients with refractory testicular cancer.Proc. ASCO, 22: 464, 1981.
7.
ForastiereA.A., HakesT.B., WittesJ.T., WittesR.E.: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules.Am. J. Clin. Oncol., 5: 243–247, 1982.
KolarićK., RothA.: Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumor activity in previously untreated patients with metastatic breast cancer.Cancer Chemother. Pharmacol., 11: 108–112, 1983.
10.
KonitsP.H., Van EchoD.A., AisnerJ., MorrisD., WiernikP.H.: Doxorubicin plus VP16-213 for the treatment of refractory breast carcinoma.Am. J. Clin. Oncol., 5: 515–519, 1982.
11.
MabelJ.A., LittleA.D.: Therapeutic synergism in murine tumors for combinations of cis-diam-minedichloroplatinum with VP16-213 or BCNU.Proc. AACR and ASCO, 20: 230, 1979.
12.
RubinJ., DeckerD.A., AhmannD.L., EaganR.T., IngleJ.N., HahnR.G.: An evaluation of two schedules of VP16 and adriamycin on patients with advanced breast cancer.Oncology, 37: 149–151, 1980.
13.
SchabelF., TraderM.W., LasterW.K., CorbettT.H., GriswoldD.P.: Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumours of mice.Cancer Treat. Rep., 63: 1459–1473, 1979.
14.
SchellF.C., YapN.Y.: A phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.Cancer Chemother. Pharmacol., 7: 223–225, 1982.
15.
SierockiJ.S., HilarisB.S., HopfanS., MartiniN., BartonD., GolbeyR.B., WittesR.E.: Cis-dichlorodiammineplatinum (II) and VP16-213: an effective induction regimen for small cell carcinoma of the lung.Cancer Treat. Rep., 63: 1593–1597, 1979.
16.
SnodgrassW., WalkerL., HeidemanR., OdomL.F., HaysT., TubergenD.G.: Kinetics of VP-16 epipodophyllotoxin in children with cancer.Proc. AACR and ASCO, 21: 333, 1980.
17.
VaughnC.B., PanettiereF., ThigpenT., BottomleyR., HoogstratenB., SamalB.: Phase II evaluation of VP16-213 in patients with advanced breast cancer. A Southwest Oncology Group Study.Cancer Treat. Rep., 65: 443–445, 1981.
18.
VaughnC.B., Maniscalco-GrebE., LockhardC., GroshkoG., EnochsK., DuffinH., DemitrishM.: VP-16 and adriamycin in patients with advanced breast cancer.Am. J. Clin. Oncol., 5: 505–507, 1982.
19.
W.H.O.Handbook for reporting results of cancer treatment.W.H.O. offset Publ. no. 48, GenevaW.H.O., 1979.
20.
YapH.Y., SalemP., HortobagyG.N., BodeyG.P., BuzdarA.U., TashimaC.K., BlumensheinG.R.: Phase II study of cis-diamminedichloroplatinum (CDDP) in advanced breast and colorectal carcinomas.Cancer Treat. Rep;, 62: 405–408, 1978.
